FDA Approves Orzeyful (oveporexton) to Treat the Underlying Cause of Narcolepsy Type 1
RegulatoryapprovedOrzeyfulPositive
AI Analysis
Summary
Takeda announced FDA approval of Orzeyful (oveporexton), an oral orexin receptor 2 agonist, for treating the underlying cause of Narcolepsy Type 1. This is a significant regulatory milestone for the company's neurology franchise.
Outcome Details
FDA approved Orzeyful (oveporexton), an oral orexin receptor 2 (OX2R) agonist, to treat the underlying cause of Narcolepsy Type 1
Importance:8/10
Sentiment:
0.90
FDA approvalNarcolepsyTakedaOrzeyfulRegulatory
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on August 5, 2026 1:08 AM